Scholar Rock, Inc.
Clinical trials sponsored by Scholar Rock, Inc., explained in plain language.
A biopharmaceutical company developing therapies targeting growth factors for neuromuscular and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a muscle-boosting antibody help people with spinal muscular atrophy over the long haul? Results expected Nov 2026 (estimated) May already have reported ↗
- New drug SRK-439 tested for safety in healthy adults Results expected Dec 2026 (estimated)
-
New drug hopes to boost muscle power in babies with SMA
Disease control Recruiting nowThis study tests a drug called apitegromab in children under 2 years old who have spinal muscular atrophy (SMA), a genetic condition that causes muscle weakness. The drug works by blocking a protein that limits muscle growth. Researchers want to see if adding apitegromab to stand…
Phase 2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug aims to build muscle in rare muscular dystrophy
Disease control Recruiting nowThis Phase 2 study tests a drug called apitegromab in 60 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes muscle weakness. Participants will receive either the drug or a placebo every 4 weeks for a year. The main goal is to see if the dru…
Phase 2 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug SRK-439 tested for safety in healthy adults
Knowledge-focused Recruiting nowThis Phase 1 trial is testing the safety and tolerability of a new drug called SRK-439 in 76 healthy adults aged 18 to 55. Participants receive either a single or multiple doses of the drug or a placebo by injection. The study measures side effects, lab tests, and how the drug mo…
Phase 1 • Sponsor: Scholar Rock, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC